Shiga toxin, Shiga-like toxin I (SLT-I) and Shiga-like toxin II (SLT-II) are cell-associated cytotoxins that kill both Vero cells and HeLa cells, whereas Shiga-like toxin II variant (SLT-IIv) is an extracellular cytotoxin that is more cytotoxic for Vero cells than for HeLa cells. The basis for these differences in cytotoxin localization and host cell specificity were examined in this study. The...

Infection with Shiga toxin- and Shiga-like toxin-producing strains of Shigella dysenteriae and Escherichia coli, respectively, can progress to the hemolytic-uremic syndrome. It has been hypothesized that circulating Shiga toxin, Shiga-like toxins, and endotoxins may contribute to the disease by directly damaging glomerular endothelial cells. The effects of these toxins on HeLa, Vero, and human ...

The B subunit of Shiga toxin and the Shiga-like toxins (SLTs) mediates receptor binding, cytotoxic specificity, and extracellular localization of the holotoxin. While the functional receptor for Shiga toxin, SLT type I (SLT-I), and SLT-II is the glycolipid designated Gb3, SLT-II variant (SLT-IIv) may use a different glycolipid receptor. To identify the domains responsible for receptor binding, ...

shiga toxin (stx) is the principal virulence factor of shigatoxigenic escherichia coli (stec), a food-born pathogen associated disease with uncomplicated diarrhea or the hemolytic-uremic syndrome. in this study, rabbit polyclonal anti recombinant a, b subunits of shiga toxin and holotoxin antisera were raised and employed for immunological purpose. by immunoblotting, these antisera recognized r...

Hemolytic-uremic syndrome is a clinical syndrome characterized by acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia that often follows infection by Shiga toxinor verotoxin-producing strains of Escherichia coli. Because thrombocytopenia and platelet activation are hallmark features of hemolytic-uremic syndrome, we examined the ability of Shiga toxin to bind platelets b...

We have determined the nucleotide sequence of the sltA and sltB genes that encode the Shiga-like toxin (SLT) produced by Escherichia coli phage H19B. The amino acid composition of the A and B subunits of SLT is very similar to that previously established for Shiga toxin from Shigella dysenteriae 1, and the deduced amino acid sequence of the B subunit of SLT is identical with that reported for t...

The Shiga toxin family consists of Shiga toxin (Stx) that is produced as a virulence factor by Shigella dysenteriae, and the Shiga-like toxins produced by certain strains of enterohemorrhagic E. coli as well as by some other types of bacteria. Infection with bacteria producing these toxins is a threat to human health even in industrialized countries, as the initial diarrhea caused by the infect...

bacterial protein toxins have been exploited as therapeutic agents and as vaccines. an issue of deserving interest is development of new generations of vaccines and immune adjuvants. in this study an active assembled recombinant shiga toxin of escherichia coli (rstx1) and its derivatives, recombinant a and b subunits (stx1-a and stx1-b), were used to immunize mice. the elicited antibody respons...

Shiga-like toxin-producing (SLTEC) Escherichia coli strains are one of the most important food borne emerging pathogens. One hundred and fifty-seven E. coli strains isolated from 39 children with diarrhea of unknown origin and one hundred and five E. coli strains from 20 healthy children were examined for Shiga-like toxin production in Vero cell line assay. The synthesis of Shiga-like toxin was...

Shiga toxin is a bacterial toxin consisting of A and B subunits. Generally, the essential cytotoxicity of the toxin is thought to be mediated by the A subunit, which possesses RNA cleavage activity and thus induces protein synthesis inhibition. We previously reported, however, that the binding of the Shiga toxin 1-B subunit to globotriaosyl ceramide, a functional receptor for Shiga toxin, induc...